Development PipelineEnfortumab vedotin

an antibody–drug conjugate being investigated in urothelial carcinoma and other solid tumors

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

EV-302/KEYNOTE-A39: Untreated locally advanced or metastatic urothelial cancer (EV + pembrolizumab vs chemotherapy)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

KEYNOTE-905/EV-303: MIBC, ineligible for/decline cisplatin (perioperative pembrolizumab ± EV + RC + PLND vs RC + PLND alone)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

KEYNOTE-B15/EV-304: Cisplatin-eligible MIBC (perioperative EV + pembrolizumab + RC + PLND vs neoadjuvant chemotherapy + RC + PLND)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

EV-103/KEYNOTE-869: Urothelial cancer (EV alone or with other therapies)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

EV-202: Locally advanced or metastatic malignant solid tumors (EV alone)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

EV-104: Non–muscle invasive bladder cancer (intravesical EV alone)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of enfortumab vedotin and ongoing clinical trials

Detailed information about enfortumab vedotin clinical trials

Related Videos

Enfortumab Vedotin Proposed Mechanism of Action